Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02025426 · Duke University · PHASE4 · terminated · last registry update 2020-10-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Significant challenges recruiting a difficult patient population with most surgeries occurring out of hours” | – | Registry record, Duke University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-10-07Results posted on the registry: Kimberly S Jones, Valproic Acid (VPA) + Dihydroergotamine (DHE) (NCT03885154)
- 2021-10-07Also stopped (terminated): Kimberly S Jones, Valproic Acid (VPA) + Dihydroergotamine (DHE) (NCT03885154)
- 2021-09-13Results posted on the registry: University of Colorado, Denver, Bromocriptine (NCT02544321)
- 2021-08-20Phase 3 first posted: University of Turin, Italy, Noradrenaline (NCT05014581)
- 2021-08-12Phase 3 first posted: Rennes University Hospital, Fludrocortisone + Placebo (NCT05001854)
- 2021-08-02Results posted on the registry: Jordan Schultz, Terazosin 5 MG + Placebo oral capsule (NCT03905811)
- 2021-07-02Results posted on the registry: University of Washington, Fluoxetine + Fluvoxamine (NCT02655354)
- 2021-07-01Results posted on the registry: VA Office of Research and Development, a drug against ADRA1A (NCT01030874)
- 2021-06-25Phase 3 first posted: Satsuma Pharmaceuticals, Inc., Dihydroergotamine + Placebo (NCT04940390)
- 2021-06-24Results posted on the registry: University of California, San Francisco, Bromocriptine 5 MG + Acetaminophen 650 MG (NCT03496545)
- 2021-05-05Also stopped (terminated): Vanderbilt University, Pseudoephedrine + 480 ml water + Pseudoephedrine + 50 ml water (NCT02149901)
- 2021-04-14Results posted on the registry: VA Office of Research and Development, doxazosin + placebo (NCT02500602)
- 2021-04-12Results posted on the registry: New York State Psychiatric Institute, Intranasal Oxycodone (NCT03415581)
- 2021-04-12Also stopped (terminated): New York State Psychiatric Institute, Intranasal Oxycodone (NCT03415581)
- 2021-03-22Also stopped (terminated): Cambridge University Hospitals NHS Foundation Trust, Albuterol Sulfate + Nicardipine Hydrochloride (NCT03098680)
- 2021-03-18Results posted on the registry: University of Wisconsin, Madison, Doxazosin (NCT02989493)
- 2021-02-24Also stopped (withdrawn): EMS, MIGRANE + PARCEL (NCT01408069)
- 2021-02-12Results posted on the registry: Impel Pharmaceuticals, INP104 (NCT03557333)
- 2020-12-29Results posted on the registry: Seattle Institute for Biomedical and Clinical Research, Prazosin + Naltrexone (NCT02322047)
- 2020-11-20Phase 3 first posted: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% + Phentolamine Ophthalmic Solution Vehicle (Placebo) (NCT04638660)
- 2020-11-06Phase 3 first posted: Opus Genetics, Inc, Phentolamine Ophthalmic Solution 0.75% (NCT04620213)
- 2020-11-03Phase 3 first posted: Ataturk University, ondansetron + Granisetron (NCT04613726)
- 2020-10-27Results posted on the registry: Bausch & Lomb Incorporated, Ketotifen/naphazoline + Ketotifen (NCT00769886)
- 2020-10-27Results posted on the registry: Bausch & Lomb Incorporated, Ketotifen/naphazoline + Naphazoline (NCT00770133)
- 2020-09-30Phase 3 first posted: Australian and New Zealand Intensive Care Research Centre, Vasopressor (NCT04569942)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision